SCHEMBL9625850

SCHEMBL9625850

O=C(Cl)OC1CC(F)(F)C1(F)F

nearest known ligand 0.30

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.30
NR1H2 P55055 1/20 0.30
NR1H3 Q13133 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10704646 0.82 NR1H2 (0.30) NR1H2NR1H3
SCHEMBL10779437 0.80
SCHEMBL11828570 0.73
SCHEMBL7624875 0.71
SCHEMBL13430319 0.70 NR1H2 (0.32) NR1H2NR1H3
SCHEMBL7755221 0.67 CHRNB2 (0.31)
SCHEMBL1767015 0.67
SCHEMBL1767012 0.65
SCHEMBL27850693 0.65 APLNR (0.31)
SCHEMBL3997449 0.62 SCN9A (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4387980-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. (US) 2024-06-26 EP disclosed
WO-2023023631-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. (US) 2023-02-23 WO disclosed
WO-2023023631-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. (US) 2023-02-23 WO disclosed
EP-3177617-B1 PIPERAZINE DERIVATIVES AS LIVER X RECEPTOR MODULATORS VITAE PHARMACEUTICALS LLC (US) 2019-10-09 EP disclosed
EP-3177617-B1 PIPERAZINE DERIVATIVES AS LIVER X RECEPTOR MODULATORS VITAE PHARMACEUTICALS LLC (US) 2019-10-09 EP disclosed
US-10144715-B2 Piperazine derivatives as liver X receptor modulators VITAE PHARMACEUTICALS, INC. (US) 2018-12-04 US disclosed
US-20170226067-A1 PIPERAZINE DERIVATIVES AS LIVER X RECEPTOR MODULATORS VITAE PHARMACEUTICALS, INC. (US) 2017-08-10 US disclosed
US-20170226067-A1 PIPERAZINE DERIVATIVES AS LIVER X RECEPTOR MODULATORS VITAE PHARMACEUTICALS, INC. (US) 2017-08-10 US disclosed
US-20170226067-A1 PIPERAZINE DERIVATIVES AS LIVER X RECEPTOR MODULATORS VITAE PHARMACEUTICALS, INC. (US) 2017-08-10 US disclosed
EP-3177617-A1 PIPERAZINE DERIVATIVES AS LIVER X RECEPTOR MODULATORS Vitae Pharmaceuticals, Inc. (US) 2017-06-14 EP disclosed
EP-0126026-A1 Process for dyeing silk or silk-containing fibrous material blends CIBA-GEIGY AG (CH) 1984-11-21 EP disclosed
EP-0126025-A1 Process for dyeing silk or silk-containing fibrous material blends CIBA-GEIGY AG (CH) 1984-11-21 EP disclosed
EP-0043411-B1 REACTIVE DISAZO DYESTUFFS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN DYEING AND PRINTING MATERIALS CONTAINING NITROGEN AND/OR HYDROXYLE GROUPS BAYER AG (DE) 1984-07-11 EP disclosed
EP-0097289-A2 Azo dyestuffs BAYER AG (DE) 1984-01-04 EP disclosed
EP-0013936-B1 REACTIVE AZO DYESTUFFS, THEIR PREPARATION AND THEIR USE IN DYEING MATERIALS CONTAINING HYDROXYL GROUPS AND AMIDE GROUPS BAYER AG (DE) 1982-09-22 EP disclosed
EP-0053320-A2 Process for the preparation of phthalocyanin compounds BAYER AG (DE) 1982-06-09 EP disclosed
EP-0050266-A1 Reactive disazo dyes, process for their preparation and their use in dyeing and printing materials that contain hydroxyl and/or nitrogen BAYER AG (DE) 1982-04-28 EP disclosed
EP-0047863-A2 Reactive phthalocyanine hyes, process for their preparation and their use in dyeing materials containing hydroxyle groups and/or nitrogen BAYER AG (DE) 1982-03-24 EP disclosed
EP-0043411-A2 Reactive disazo dyestuffs, process for their preparation and their use in dyeing and printing materials containing nitrogen and/or hydroxyle groups BAYER AG (DE) 1982-01-13 EP disclosed
EP-0013936-A1 Reactive azo dyestuffs, their preparation and their use in dyeing materials containing hydroxyl groups and amide groups BAYER AG (DE) 1980-08-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170226067-A1 PIPERAZINE DERIVATIVES AS LIVER X RECEPTOR MODULATORS NR1H2, NR1H3, NR1I2 GPR119 31/4885NR1H2 1/4885NR1H3 2/4885
US-10144715-B2 Piperazine derivatives as liver X receptor modulators NR1H2, NR1H3, NR1I2 GPR119 31/4885NR1H2 1/4885NR1H3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.